Publications by authors named "E Mateos"
Sustained antiviral response against HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
Mario Manzanares Fernando Ramos-Martín Sara Rodríguez-Mora Guiomar Casado-Fernández Clara Sánchez-Menéndez Elena Mateos
Front Pharmacol
September 2024
Article Synopsis
- - HIV-1 infection persists due to long-term viral reservoirs in latently infected CD4 T cells, prompting the need for strategies to stimulate cytotoxic immunity, including the "Shock and Kill" approach.
- - Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, has shown effectiveness against HIV-1 and may enhance the immune response against both cancer and viral infections.
- - In a study of patients with chronic myeloid leukemia who switched from imatinib to ponatinib, results indicated that ponatinib treatment significantly reduced HIV-1 infection rates and increased the cytotoxic response from peripheral blood mononuclear cells, with effects lasting at least 12 months post-treatment.
Article Synopsis
- After mild COVID-19, some individuals develop a condition called Post-COVID condition (PCC) characterized by lingering symptoms and persistent immune system changes.
- A study compared the immune responses of people with PCC to those with mild, severe, and critical COVID-19, focusing on specific CD4+ T helper cell types.
- Results indicated that people with PCC had a unique immune profile, including low Th1 cells, high Th2 response, and elevated pro-inflammatory Th9 and Th17 cells, which may hinder the body's ability to fight off infections and contribute to prolonged symptoms.
Article Synopsis
- * Dasatinib, a medication used for chronic myeloid leukemia, shows promise against HIV-1 by preserving the antiviral activity of the SAMHD1 protein in CD4+ T cells and reducing the phosphorylation that inactivates it, inhibiting HIV-1 infection in macrophages.
- * Short-term dasatinib treatment lowers inflammatory cytokines in macrophages while maintaining some antiviral responses, suggesting that combining dasatinib with ART could effectively target HIV-1 reservoirs and reduce inflammation in people living with HIV.
Introduction: HIV-1 infection may produce a detrimental effect on the immune response. Early start of antiretroviral therapy (ART) is recommended to preserve the integrity of the immune system. In fact, people with HIV (PWH) and normal CD4/CD8 ratio appear not to be more susceptible to severe forms of COVID-19 than the general population and they usually present a good seroconversion rate in response to vaccination against SARS-CoV-2.
View Article and Find Full Text PDF